Search
Close this search box.

September 13, 2023

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA) ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has

CONTINUE READING

Curia soutient l’essai clinique de phase 1 de Replicate Bioscience sur un vaccin novateur à base d’ARN de nouvelle génération

L’entreprise apporte une substance médicamenteuse fabriquée selon les BPFa afin de permettre la première étude clinique chez un être humain du nouvel ARN auto-répliquant (ARNar) RBI-4000 ALBANY, ÉTAT DE NEW YORK, 13 sept. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, développement et fabrication en sous-traitance de premier plan,

CONTINUE READING

SEARCH & HIT ENTER